GoodRx Holdings, Inc.
HealthcareNASDAQ:GDRX · NASDAQ Global Select
+$0.02 today
Vol 0.67M · Avg 1.63M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$787.9M of revenue converted into $20.6M of net income for the selected period. Gross margin is 86.6% and net margin is 2.6%, showing how much revenue survives after costs and taxes. EPS is $0.06, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $796.9M +0.6% | $792.3M +5.6% | $750.3M -2.1% | $766.6M +2.8% | $745.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $57.6M +19.5% | $48.2M -28.0% | $66.9M +2.8% | $65.1M +39.3% | $46.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $739.3M -0.7% | $744.1M +8.9% | $683.3M -2.6% | $701.5M +0.4% | $698.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 92.8% -1.1pp | 93.9% +2.8pp | 91.1% -0.4pp | 91.5% -2.2pp | 93.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $121.0M -2.2% | $123.7M -8.9% | $135.8M -5.1% | $143.1M +13.7% | $125.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $445.5M -8.1% | $485.0M +3.9% | $466.8M -7.1% | $502.4M -4.3% | $524.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $651.8M -3.9% | $678.3M -4.5% | $710.3M +1.5% | $699.7M +2.1% | $685.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $85.2M +22.5% | $69.5M -35.4% | $107.7M +98.7% | $54.2M +56.9% | $34.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $184.4M +19.8% | $153.9M +41.4% | $108.8M +66.9% | $65.2M +35.8% | $48.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 23.1% +3.7pp | 19.4% +4.9pp | 14.5% +6.0pp | 8.5% +2.1pp | 6.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $87.5M +32.9% | $65.8M +343.8% | -$27.0M -1653.9% | $1.7M -87.0% | $13.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 11.0% +2.7pp | 8.3% +11.9pp | -3.6% -3.8pp | 0.2% -1.6pp | 1.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $10.9M -53.0% | $23.3M -27.7% | $32.2M +246.9% | $9.3M +15618.6% | $59.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $42.6M -19.5% | $52.9M -6.7% | $56.7M +65.7% | $34.2M +44.8% | $23.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$31.0M +10.0% | -$34.4M -20.4% | -$28.6M -14.4% | -$25.0M -5.9% | -$23.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $56.5M +79.7% | $31.5M +156.6% | -$55.6M -139.2% | -$23.2M -128.3% | -$10.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 7.1% +3.1pp | 4.0% +11.4pp | -7.4% -4.4pp | -3.0% -1.7pp | -1.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $26.1M +73.2% | $15.1M +132.3% | -$46.7M -586.7% | $9.6M -36.3% | $15.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | $30.4M +85.7% | $16.4M +284.8% | -$8.9M +73.0% | -$32.8M -30.0% | -$25.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | 3.8% +1.8pp | 2.1% +3.3pp | -1.2% +3.1pp | -4.3% -0.9pp | -3.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +100.9% | $0 +296.8% | -$0 +73.0% | -$0 -33.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +104.1% | $0 +293.5% | -$0 +73.0% | -$0 -33.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $356.3M -7.6% | $385.7M -6.0% | $410.3M -0.6% | $412.9M +0.7% | $410.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $357.0M -9.0% | $392.2M -4.4% | $410.3M -0.6% | $412.9M +0.7% | $410.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
Innoviva, Inc.
NASDAQ:INVA
$1.68B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
IRadimed Corporation
NASDAQ:IRMD
$1.20B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
HealthStream, Inc.
NASDAQ:HSTM
$763.39M
MiMedx Group, Inc.
NASDAQ:MDXG
$536.20M
Claritev Corporation
NYSE:CTEV
$526.61M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GDRX generate?
GoodRx Holdings, Inc. (GDRX) reported $796.85M of revenue in fiscal 2025.
Is GDRX profitable?
GoodRx Holdings, Inc. (GDRX) reported $30.44M of net income, with a net margin of 3.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.